Sphere Bio Launches Cyto-Cellect IgG Kappa and Viability Assay Kit for Single-Cell Selection

Sphere Bio Launches Cyto-Cellect IgG Kappa and Viability Assay Kit for Single-Cell Selection Sphere Bio, a leader in picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, has unveiled the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit. This is…

Read MoreSphere Bio Launches Cyto-Cellect IgG Kappa and Viability Assay Kit for Single-Cell Selection

Convatec Partners with Leading Wound, Ostomy, and Continence Nursing Organization

Convatec Partners with Leading Wound, Ostomy, and Continence Nursing Organization Convatec, a global leader in medical products and technologies focused on managing chronic conditions, has announced an exciting new collaboration with the Wound, Ostomy, and Continence Nurses Society™ (WOCN®), the…

Read MoreConvatec Partners with Leading Wound, Ostomy, and Continence Nursing Organization

GE HealthCare Acquires Nihon Medi-Physics, Leading Radiopharmaceutical Company in Japan

GE HealthCare Acquires Nihon Medi-Physics, Leading Radiopharmaceutical Company in Japan GE HealthCare Technologies Inc. (Nasdaq: GEHC) has successfully completed its acquisition of the remaining 50% stake in Nihon Medi-Physics Co., Ltd (NMP) from Sumitomo Chemical, thereby securing full ownership of…

Read MoreGE HealthCare Acquires Nihon Medi-Physics, Leading Radiopharmaceutical Company in Japan

Novotech Secures New Investment from GIC, Temasek, and TPG to Boost Global Growth

Novotech Secures New Investment from GIC, Temasek, and TPG to Boost Global Growth Novotech, a leading full-service biotech clinical research organization (CRO), announced today that affiliates of GIC and Temasek have entered into binding agreements to acquire a significant stake…

Read MoreNovotech Secures New Investment from GIC, Temasek, and TPG to Boost Global Growth

ACC 2025: Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively

ACC 2025: Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company focused on non-invasive cardiac assessments, recently showcased promising clinical findings from a study on its AI-powered Cardiac Performance System (CPS™) at the American College of…

Read MoreACC 2025: Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively
Colorectal Cancer Screening Market to Hit $46.1B by 2029 – ResearchAndMarkets.com

Colorectal Cancer Screening Market to Hit $46.1B by 2029 – ResearchAndMarkets.com

Colorectal Cancer Screening and Diagnostics Market Report Summary Market Overview The “Colorectal Cancer Screening and Diagnostics Market” report provides an in-depth analysis of the colorectal cancer screening and diagnostic testing industry. This comprehensive study includes a market snapshot, company profiles…

Read MoreColorectal Cancer Screening Market to Hit $46.1B by 2029 – ResearchAndMarkets.com
CRISPR Cas9 Market Poised for Rapid Growth with Gene Therapy Advances – 2024 Report

CRISPR Cas9 Market Poised for Rapid Growth with Gene Therapy Advances – 2024 Report

CRISPR Cas9 Market Set for Exponential Growth with Gene Therapy Advancements The latest “CRISPR Cas9 Market” report has been added to ResearchAndMarkets.com’s offerings, highlighting the transformative potential of CRISPR/Cas9 technology in medicine and biotechnology. This breakthrough gene-editing tool is set…

Read MoreCRISPR Cas9 Market Poised for Rapid Growth with Gene Therapy Advances – 2024 Report
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis

Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis

Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a pioneering biotechnology company and a spin-off of 4P-Pharma, has received authorization from Health Canada to initiate its Phase 2a INFLAM MOTION clinical trial. This study…

Read MoreHealth Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis